Flo Health denies unlawfully sharing personal data with Meta

Flo Health is facing a data privacy lawsuit for allegations that it unlawfully shared users’ personal period-tracking data with Meta for targeted advertising.

The firm, which became Europe’s first FemTech unicorn in July 2024 after raising more than $200 million (£155.7m) in Series C investment, denies the claims.

Sifted reported that the case began in San Francisco on 21 July 2025 and is expected to last at least eight days, involving five named claimants who argue they never gave permission for their data about the dates and lengths of the periods to be shared.

Claimants are seeking $1,000 in statutory damages under California’s medical privacy law for 13 million Flo users who downloaded and registered on the app between late 2016 and early 2019, legal publication Law360 reported, meaning it could face $13bn in damages.

They say that Flo integrated tracking tools including Meta’s software development kits, which automatically transmitted sensitive personal data as users engaged with the app.

In a statement Flo said: “Flo is committed to protecting the privacy of its users, and any allegation otherwise has no merit. Flo has never sold user data and never will.”

Claims were also brought against Google as part of the same case, but were settled earlier in July 2025 for an undisclosed sum.

Several of the FemTech app’s users filed a suit against Flo, Google and Meta in 2021, following a settlement between Flo and the Federal Trade Commission after allegations the company shared health information with third-party advertising companies without permission.

Flo denies the claims and says it agreed to settle the matter to “avoid the time and cost associated with litigation”.

Researchers recently called for greater regulation of period tracking apps, which they said may compromise users’ privacy and reproductive autonomy.

However Sue Khan, vice president of security and data protection officer at FemTech firm Flo Health, said that the University of Cambridge paper could make women “feel unsafe about the privacy of period tracking applications”.

In an article on LinkedIn, Khan wrote: “We have never – and will never monetize or sell user data.

“We do not see personal data as a commodity, and categorically reject the notion that women’s health data should be treated as a goldmine for advertising.”